HUTCHMED (China) Limited (HCM)

Sector:

Pharma and Biotech

Index:

FTSE AIM 100

 203.00p
   
  • Change Today:
      0.000p
  • 52 Week High: 340.00
  • 52 Week Low: 189.00
  • Currency: UK Pounds
  • Shares Issued: 871.60m
  • Volume: 0
  • Market Cap: £1,769.35m
  • RiskGrade: 226
  • Beta: 0.03

Latest ShareCast News

Hutchmed enrols patients for phase two savolitinib trial

By Josh White

Date: Tuesday 22 Apr 2025

(Sharecast News) - Hutchmed China announced on Tuesday that it has completed patient enrollment for the registration phase of its phase two clinical trial, evaluating savolitinib in Chinese patients with MET-amplified gastric cancer or gastroesophageal junction adenocarcinoma.

Hutchmed renal cell carcinoma trial meets primary endpoint

By Josh White

Date: Wednesday 19 Mar 2025

(Sharecast News) - Hutchmed China, alongside Innovent Biologics, announced on Wednesday that the FRUSICA-2 phase two and three clinical trial evaluating the combination of fruquintinib and sintilimab as a second-line treatment for advanced renal cell carcinoma (RCC) in China had met its primary endpoint of progression-free survival.

Hutchmed announces progress, hits milestone with lung cancer treatment

By Josh White

Date: Thursday 02 Jan 2025

(Sharecast News) - Hutchmed China announced a number of advancements on Thursday, including a regulatory milestone for its lung cancer treatment and a substantial divestment aimed at bolstering its core business strategy.

Hutchmed to receive $10m milestone payment from ... 13-Dec-2024 ShareCast
Hutchmed lung cancer therapy gets breakthrough d... 12-Dec-2024 ShareCast
Hutchmed endometrial cancer treatment gets condi... 03-Dec-2024 ShareCast
Hutchmed partner launches Fruzaqla in Japan 22-Nov-2024 ShareCast
Hutchmed to receive $20m Fruzaqla milestone paym... 31-Oct-2024 ShareCast
Hutchmed reports positive results from AstraZene... 16-Oct-2024 ShareCast
Hutchmed partner Takeda gets Japanese approval f... 24-Sep-2024 ShareCast
Hutchmed to present new and updated clinical tri... 09-Sep-2024 ShareCast
Hutchmed withdraws supplemental new drug applica... 30-Aug-2024 ShareCast
Oncology revenue drives first-half growth for Hu... 31-Jul-2024 ShareCast
Hutchmed gets tazemetostat new drug application ... 04-Jul-2024 ShareCast
Hutchmed partner gets European approval for fruq... 24-Jun-2024 ShareCast
Hutchmed publishes positive sovleplenib trial re... 17-Jun-2024 ShareCast
Hutchmed China launches two cancer treatment tri... 14-May-2024 ShareCast
Hutchmed China to make several presentations at ... 05-Apr-2024 ShareCast
Hutchmed endometrial cancer treatment gets prior... 02-Apr-2024 ShareCast
Hutchmed cancer treatment indication accepted fo... 28-Mar-2024 ShareCast
 

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

HCM Market Data

Currency UK Pounds
Share Price 203.00p
Change Today 0.000p
% Change 0.00 %
52 Week High 340.00
52 Week Low 189.00
Volume 0
Shares Issued 871.60m
Market Cap £1,769.35m
Beta 0.03
RiskGrade 226

HCM Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
40.64% below the market average40.64% below the market average40.64% below the market average40.64% below the market average40.64% below the market average
25% below the sector average25% below the sector average25% below the sector average25% below the sector average25% below the sector average
Price Trend
56.6% below the market average56.6% below the market average56.6% below the market average56.6% below the market average56.6% below the market average
4.17% below the sector average4.17% below the sector average4.17% below the sector average4.17% below the sector average4.17% below the sector average
Income Not Available
Growth
45.11% below the market average45.11% below the market average45.11% below the market average45.11% below the market average45.11% below the market average
75% below the sector average75% below the sector average75% below the sector average75% below the sector average75% below the sector average

HCM Dividends

No dividends found

Trades for --2025

Time Volume / Share Price
0 @ 0.000p

HCM Key Personnel

Chair Dan Eldar
CEO Weiguo Su

Top of Page